Developing Next-Generation Immunotherapies for Cancer Patients
The introduction of new checkpoint inhibitor (CPI) immunotherapies into the clinic has significantly improved the prognosis for many cancer patients over the last decade, but the overall response rates remain relatively low in all tumor types. There remains a significant unmet need to improve overall and long-term survival for cancer patients. New innovation and enhancements to the currently available therapies are urgently needed to address the treatment gaps.
Next-generation cancer treatments require:
Improving survival for CPI non-responders (70%-80%)
Reprogramming the immune system to attack cancer
Integrating linnate and adaptive immune responses
Addressing cancer immune resistance
Kineta is building next-generation immunotherapies to address the major challenges with current cancer treatments. We aim to improve outcomes for cancer patients by solving the problems of cancer resistance. Our novel drug programs are focused on addressing and correcting immuno-suppression, exhausted T-cells and poor tumor immunogenicity.
Kineta Pipeline
Kineta’s mission is to develop next-generation immunotherapies that transform patients’ lives. Kineta is focused on developing fully human antibodies that address the mechanisms of cancer immune resistance.
Drug Program
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
Anticipated Milestones
Indications:
Advanced solid tumors
NSCLC, CRC, OC
4Q 2022: IND Approval & Initiate Phase 1
2Q 2023: Initiate pembrolizumab combo cohort
Q4 2023: Initial Phase 1 data readout
Indications:
Advanced solid tumors
1H 2024: IND filing
1H 2024: Start Phase 1 clinical study
